UA Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
Researchers at the University of Arizona College of Medicine – Phoenix have shown for the first time in preclinical studies that Aliskiren, a drug that inhibits the enzyme that regulates blood pressure, can delay the progression of congestive heart failure and lengthen survival rates.
More than 5 million Americans live with congestive heart failure, a chronic progressive condition that occurs when the heart muscle doesn’t pump blood as well as it should.
The Arizona Center for Drug Discovery and the University of Arizona Cancer Center will host a one-day summit, “Discovering New Medicines in Arizona,” at the Phoenix Biomedical Campus on Wednesday, Oct. 2.
The inaugural “Southwest Regional Advances in Digestive Diseases: Best of DDW” 4.0-CME, half-day conference, hosted Sept. 7 at the J.W.
